To read each patient's story, click on their image.
Oncology Impact Partners (OIP) is committed to improving cancer patient outcomes by partnering with the most promising cancer therapeutic and diagnostic companies, and by supporting non-profit academic research in oncology.
Oncology Impact Partners management has committed to donating 10% of the carried interest it receives to cancer related charities, including 5% to the National Foundation for Cancer Research (NFCR) to support non-profit, academic cancer research and 5% to other cancer related charities.
The National Foundation for Cancer Research (NFCR) was founded in 1973 by Franklin Salisbury Sr. and Noble Laureate Albert Szent-György to support non-profit, academic cancer research and public education relating to the prevention, early diagnosis, and treatment of cancer. NFCR promotes and facilitates collaboration among scientists to accelerate the pace of discovery from bench to bedside both within the US and globally. OIP's donations will allow NFCR to further its mission. To learn more about NFCR, visit the Foundation's website at www.nfcr.org.
Oncology Impact Partners recognizes that most standard-of-care cancer treatments, as well as the technologies in which it invests, originated in academic and other non-profit cancer research centers. Recognizing the cycle of innovation between the for- and non-profit worlds, and the need to support future academic discoveries, OIP's management has committed to providing financing in the form of donations and strategic advise to non-profit academic labs.
In addition to donating to non-profit cancer research, OIP is committed to supporting technologies that improve patient outcomes, lower the cost of care, and democratize access to advanced therapeutics and diagnostics. OIP seeks to fill the void in late pre-clinical and early clinical funding while providing strategic development support to portfolio companies during this critical stage.